# Palbociclib + Ganitumab In Ewing Sarcoma

> **NCT04129151** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Ewing Sarcoma
- Ewing's Sarcoma Recurrent

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Ganitumab

## Key facts

- **NCT ID:** NCT04129151
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-05
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study closed early due to discontinuation of ganitumab supply.
- **Last updated:** 2024-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04129151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04129151, "Palbociclib + Ganitumab In Ewing Sarcoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04129151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*